| 1 |
34954416 | Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy. | 2022 Mar 1 |
4 |
| 2 |
34274531 | Dually targeted bioinspired nanovesicle delays advanced prostate cancer tumour growth in vivo. | 2021 Oct 15 |
1 |
| 3 |
32657590 | Correction to "Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design". | 2020 Aug 3 |
1 |
| 4 |
30802065 | Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design. | 2019 Apr 1 |
11 |
| 5 |
24586533 | Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. | 2014 |
4 |
| 6 |
24900200 | Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen. | 2010 Aug 12 |
3 |
| 7 |
19815486 | Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. | 2009 Oct |
1 |
| 8 |
17973264 | Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). | 2008 Mar 1 |
2 |
| 9 |
16211657 | Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. | 2005 Oct |
1 |
| 10 |
15129984 | Assessing aggregation of peptide conjugate of doxorubicin using quasi-elastic light scattering and 600 MHz NMR. | 2004 Mar 1 |
1 |
| 11 |
15540784 | Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. | 2004 Nov |
4 |
| 12 |
11919247 | Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. | 2002 Apr 1 |
1 |
| 13 |
11550207 | Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. | 2001 Sep 15 |
1 |
| 14 |
11708923 | The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. | 2001 Nov 22 |
1 |
| 15 |
10960846 | In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. | 2000 Sep 15 |
7 |
| 16 |
11062536 | A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. | 2000 Nov |
5 |
| 17 |
10091767 | Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. | 1999 Feb 15 |
1 |
| 18 |
10368631 | Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. | 1999 Mar-Apr |
2 |
| 19 |
9635575 | Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. | 1998 Jun 15 |
2 |
| 20 |
8738407 | Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? | 1996 |
1 |